What is the duration of action of immediate-release Dilaudid (hydromorphone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Immediate-Release Dilaudid (Hydromorphone) Dosing Interval

Immediate-release Dilaudid (hydromorphone) should be dosed every 4 to 6 hours based on its duration of action. 1

Duration of Action

  • Immediate-release hydromorphone has a duration of action of 4-5 hours after oral administration 1
  • The onset of action occurs within 15-30 minutes of administration 1
  • Peak plasma concentrations are achieved within ½ to 1 hour after oral dosing, with the terminal elimination half-life approximately 2.3 to 2.6 hours 2

Clinical Pharmacology

  • After oral administration of immediate-release hydromorphone, the analgesic effects peak within 1.5 hours and are maintained at greater than 50% of peak effect for approximately 3.6 hours 3
  • The short duration necessitates frequent dosing every 4 hours with conventional immediate-release formulations to provide sustained pain relief 3
  • Hydromorphone undergoes extensive first-pass metabolism with approximately 24% bioavailability after oral administration 2

Comparison with Extended-Release Formulation

  • Extended-release hydromorphone formulations provide once-daily dosing by maintaining therapeutic levels for over 20 hours, contrasting sharply with the 4-6 hour duration of immediate-release formulations 1, 4
  • When converting from immediate-release to extended-release, the total daily dose remains the same but is administered once daily rather than divided into multiple doses 4

Important Caveats

  • In patients with moderate hepatic impairment (Child-Pugh B), exposure increases 4-fold, requiring lower starting doses and extended dosing intervals 2
  • In patients with severe renal impairment (CrCl <30 mL/min), the elimination half-life extends to approximately 40 hours compared to 15 hours in normal function, necessitating significantly longer dosing intervals 2
  • The 4-6 hour dosing interval applies to patients with normal hepatic and renal function; dose adjustments and interval extensions are mandatory in organ dysfunction 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Converting from Immediate-Release to Extended-Release Hydromorphone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.